MSD Korea celebrates 30th anniversary with focus on 'healthy changes led by the company'

By Yoo, Ha Eun, THE BIO - MSD Korea, the Korean branch of the multinational pharmaceutical company MSD (Merck, USA), announced on September 9 that it celebrated its 30th anniversary by highlighting the 'healthy changes' the company has driven through innovation over the past 30 years. Around 600 employees and their families participated to celebrate the anniversary.

Since its establishment in September 1994, MSD Korea has played a key role in improving public health in Korea by providing advanced medical solutions and information, particularly in areas lacking treatment and prevention options. Over the past 30 years, the company has introduced 15 innovative drugs and vaccines that were previously unavailable in Korea. Currently, MSD Korea supplies around 50 essential medicines and vaccines, including immunotherapy anticancer drugs, vaccines for national immunization programs, and new antibiotics to combat antibiotic-resistant bacteria. According to MSD Korea, around 2.4 million Koreans used its products last year alone.

MSD Korea is also heavily investing in research and development (R&D) to provide new treatment and infection prevention methods to more Koreans. The company is collaborating extensively with local research institutes and academic institutions, and is currently involved in 185 clinical studies with 600 research partners. Over the past five years, MSD Korea has received approval for an average of 20 new clinical studies per year from the Ministry of Food and Drug Safety, making it the pharmaceutical company with the highest number of clinical trial approvals in Korea.

In addition, the company is contributing to the growth of the Korean pharmaceutical industry through various partnerships aimed at creating a healthy ecosystem for national health improvement and enhancing global competitiveness. Since 2020, MSD Korea has entered into partnerships with approximately 20 Korean biopharmaceutical companies, including agreements for technology transfer, joint research, and co-promotion.

"As a trusted partner of Korean society, the company will remain engaged in aggressing the healthcare challenges our society faces and strive to have a positive impact," stated Albert Kim, Managing Director of MSD Korea. "We plan to introduce innovative products in the domestic medical field, particularly where treatment and prevention options are limited," he added.

Source: https://www.thebionews.net/news/articleView.html?idxno=8638 

• SHARE
• 페이스북으로 보내기
• 트위터로 보내기
• 구글플러스로 보내기